COMPARISON · REVIEW DRAFT
Retatrutide and tirzepatide: reference comparison
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Reference notes
The source distinguishes investigational retatrutide from tirzepatide formulations with regulatory approval. The additional glucagon target does not provide a dose-conversion rule.
Use each compound’s own mass and concentration inputs. The reference ranges below must not be interpreted as a one-to-one substitution.
| Measure | Retatrutide | Tirzepatide |
|---|---|---|
| Targets | GLP-1 / GIP / glucagon | GLP-1 / GIP |
| Vials, mg | 5 / 10 / 20 / 30 | 5 / 10 / 15 |
| Dose range, mg | 1–12 | 2.5–15 |
| Half-life | ~6 days | ~5 days |
Source & content review 2 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Research ranges are not approved prescribing instructions. Regulatory status needs current primary-source verification before publication.
Captured source values
{
"numericalFacts": []
}